The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Ebselen: prospective therapy for cerebral ischaemia
Abstract
Stroke occurs due to haemorrhage or occlusive injury and results in ischaemia and reperfusion injury. A variety of destructive mechanisms are involved including oxygen radical generation, calcium overload, cytotoxicity and apoptosis as well as the generation of inflammatory mediators. Ebselen, 2-phenyl-1, 2-benzisoselenazol-3(2H)-one (PZ 51, DR3305), is a mimic of GSH peroxidase which also reacts with peroxynitrite and can inhibit enzymes such as lipoxygenases, NO synthases, NADPH oxidase, protein kinase C and H(+)/K(+)-ATPase. Ebselen is in a late stage of development for the treatment of stroke. The molecular actions of ebselen contribute to its anti-inflammatory and anti-oxidant properties, which have been demonstrated in a variety of in vivo models. Numerous in vitro experiments using isolated LDL, liposomes, microsomes, isolated cells and organs have established that ebselen protects against oxidative challenge. Unlike many inorganic and aliphatic selenium compounds, ebselen has low toxicity as metabolism of the compound does not liberate the selenium moiety, which remains within the ring structure. Subsequent metabolism involves methylation, glucuronidation and hydroxylation. Experimental studies in rats and dogs have revealed that ebselen is able to inhibit both vasospasm and tissue damage in stroke models, which correlates with its inhibitory effects on oxidative processes. Results from randomised, placebo-controlled, double-blind clinical studies on the neurological consequences of acute ischaemic stroke, subarachnoid haemorrhage and acute middle cerebral artery occlusion, have revealed that ebselen significantly enhances outcome in patients who have experienced occlusive cerebral ischaemia of limited duration. The benefit achieved with ebselen is closely related to the rapidity with which the treatment is initiated, following the onset of the stroke attack. Safety and tolerability are good and no adverse effects have become apparent. Ebselen is currently at the pre-registration stage for subarachnoid haemorrhage and stroke in Japan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Selenium: Biochemical Role as a Component of Glutathione Peroxidase
Rotruck, J. T., Pope, A. L., Ganther, H. E., Swanson, A. B., Hafeman, D. G., & Hoekstra, W. G. (1973) · Science · doi:10.1126/science.179.4073.588 · Cited by 7,809
Glutathione peroxidase: A selenoenzyme
Flohe, L., Günzler, W. A., & Schock, H. H. (1973) · FEBS Letters · doi:10.1016/0014-5793(73)80755-0 · Cited by 1,385
Tissue-specific functions of individual glutathione peroxidases
Brigelius-Flohé, R. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00173-2 · Cited by 1,114
The selenoenzyme phospholipid hydroperoxide glutathione peroxidase
Ursini, F., Maiorino, M., & Gregolin, C. (1985) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(85)90182-5 · Cited by 990
A novel biologically active seleno-organic compound—1
Müller, A., Cadenas, E., Graf, P., & Sies, H. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90083-2 · Cited by 828
Self-citationOxygen radical mechanisms of brain injury following ischemia and reperfusion
Traystman, R. J., Kirsch, J. R., & Koehler, R. C. (1991) · Journal of Applied Physiology · doi:10.1152/jappl.1991.71.4.1185 · Cited by 653
A novel biologically active seleno-organic compound—II
Wendel, A., Fausel, M., Safayhi, H., Tiegs, G., & Otter, R. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90084-4 · Cited by 433
Ebselen, a selenoorganic compound as glutathione peroxidase mimic
Sies, H. (1993) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(93)90028-s · Cited by 431
Self-citationTuhrim, S., Horowitz, D. R., Sacher, M., & Godbold, J. H. (1999) · Critical Care Medicine · doi:10.1097/00003246-199903000-00045 · Cited by 430
Cited by
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Sulfur and Selenium: The Role of Oxidation State in Protein Structure and Function
Jacob, C., Giles, G. I., Giles, N. M., & Sies, H. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200300573 · Cited by 756
Self-citationHanschmann, E.-M., Godoy, J. R., Berndt, C., Hudemann, C., & Lillig, C. H. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4599 · Cited by 677
Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds
Nogueira, C. W., & Rocha, J. B. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0720-3 · Cited by 477
Jacob, C. (2006) · Natural Product Reports · doi:10.1039/b609523m · Cited by 373
Metadata
- Authors
- Parnham, M., & Sies, H.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2000-03
- Volume
- 9
- Issue
- 3
- Pages
- 607-619
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2054877890
- Cited by
- 283
- References
- 47
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ebselen: prospective therapy for cerebral ischaemia. https://app.cochat.ai/papers/10.1517/13543784.9.3.607
- The paper
- Parnham, M., & Sies, H. (2000). Ebselen: prospective therapy for cerebral ischaemia. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.9.3.607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.